反应性C蛋白,状血管单元,以及阿尔茨海默氏症
Mihaela Straistă1, Mark Slevin2
1General Medicine, The George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Târgu Mureș, ROU.
Cureus
|September 30, 2024
概括
阿尔茨海默病涉及β粉样蛋白和神经炎症. 单体C反应蛋白 (mCRP) 和质血管单元 (GVU) 相互作用,恶化大脑炎症和神经退行.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默氏病 (AD) 的发病包括粉样β (Aβ) 和神经炎症.
- 质血管单元 (GVU),包括大脑血管和质细胞,如星球细胞,在AD中至关重要.
- 在AD中GVU受损导致血脑屏障崩,Aβ清除减少和慢性炎症.
研究的目的:
- 审查在阿尔茨海默病中质血管单元 (GVU) 和单体C反应蛋白 (mCRP) 之间的协同联系.
- 要突出mCRP和GVU功能障碍如何加剧神经炎症和神经退行.
- 探索针对这种相互作用的潜在治疗策略.
主要方法:
- 文献综述侧重于GVU和CRP/mCRP在AD病变发生中的作用.
- 分析表明血管因素,质细胞和炎症标志物之间的相互作用的研究.
- 综合证据将mCRP与血管透性和炎症性细胞因子扩散联系起来.
主要成果:
- C-反应蛋白 (CRP),特别是其单体形式 (mCRP),与内皮功能障碍和粉样斑块不稳定性有关.
- mCRP有助于增加血管透性,促进炎症性细胞因子进入大脑.
- 星细胞功能障碍通过增加脑血管内炎症和粉样蛋白积累而加剧AD的进展.
结论:
- 在延续AD中神经炎症和神经退行方面,GVU和mCRP之间存在协同关系.
- 了解这种相互作用为减少AD进展的新疗法目标提供了洞察力.
- 针对GVU-mCRP轴可能是AD治疗的一个有前途的策略.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
10.6K
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
63
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
63
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
